Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUPPORT trial of semaglutide for obesity and resistant hypertension
2024-513958-29-00Phase 3Authorised
- Sponsor
- Trinity College Dublin
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in resistant hypertension (RH) and obesity comparing Semaglutide arm with Placebo arm (2 arms). Primary endpoints: Variability in mean difference in systolic blood pressure after 36 weeks, Recruitment and site feasibility and 3 more. Planned start Jan 2025; status: authorised.
02
Drugs
03
Conditions
resistant hypertension (RH)obesity
Beyond the preview
Go deeper on 2024-513958-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513958-29-00.